ABL1 TYROSINE KINASE DOMAIN MUTATION ANALYSIS
ITEM ID
N939
Item Name
ABL1 TYROSINE KINASE DOMAIN MUTATION ANALYSIS
DOCTOR SPECIALITY
Hematologist, Oncologist
DISEASE DESCRIPTION
Pharmacogenomics
Test Status
Active
ABL1 TYROSINE KINASE DOMAIN MUTATION ANALYSIS
Specimen
4 mL (2 mL min.) Whole blood in 1 Lavender Top (EDTA) tube. Ship refrigerated. DO NOT FREEZE. Submit latest BCR-ABL1 Quantitative report along with sample. Physician prescription is mandatory.
Method:
NGS
Report:
Sample submitted by 2nd day of the month. Report issued in 4 weeks.
Usage:
ABL1 Tyrosine Kinase Domain mutations cause resistance to Tyrsine Kinase inhibitors, including Imatinib, Dasatinib, Niltonib among others. Exons 4 to 10 are spanned for mutations by NGS to assist in changing treatment/management for better efficiency.
Doctor Specialty:
Hematologist, Oncologist
Disease:
Pharmacogenomics
Components::
*ABL1 Tyrosine kinase domain (Exons 4 to 10) in BCR::ABL1 gene fusion
Department:
MOLECULAR DIAGNOSTICS
Pre Test Information:
Submit latest BCR-ABL Quantitative report along with sample. Physician prescription is mandatory.